Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.

A log-rank test comparing the survivor curves approached significance ( p = 0.05), though the smaller number of patients for comparison of initial dose limits the conclusions that may be drawn from this group (Fig. 2 ).

also in 8,237 other papers